| Literature DB >> 35309562 |
Shambaditya Das1, Souvik Dubey1, Suman Das1, Avijit Hazra2, Alak Pandit1, Ritwik Ghosh3, Biman Kanti Ray1.
Abstract
Introduction: Moyamoya angiopathy (MMA) is a chronic, progressive intracranial vasculopathy with variation in prevalence and clinical manifestations across different populations. This study was aimed to estimate the frequency of MMA as an etiology of stroke and its epidemiological features in the largest cohort of MMA patients in India. Method: A single-centered cross-sectional observational study over a period of 5 years (2016-2021) was undertaken among consecutive stroke and transient ischemic attack (TIA) patients to look for the presence of MMA angiographically. Each patient with angiographically proven MMA was further evaluated for demographic, clinical, and radiological characteristics.Entities:
Keywords: India; Moyamoya angiopathy; Moyamoya disease; Moyamoya syndrome; Stroke; childhood stroke; epidemiology
Year: 2022 PMID: 35309562 PMCID: PMC8931392 DOI: 10.3389/fneur.2022.837704
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Distribution graph of age frequency with (A) age at first neurological symptom and (B) age of diagnosis of moyamoya angiopathy (MMA) in our cohort.
Clinico-demographic analysis of Moyamoya angiopathy (MMA) patients.
|
|
|
|
|
|
|---|---|---|---|---|
|
|
|
| ||
| Sex ratio (M:F) | 1:1.4 | 1:1.2 | 1:1.5 | 0.525 |
| Area of residence Rural | 70.0% | 72.0% | 68.2% | |
| Urban | 30.0% | 28.0% | 31.8% | |
| Family history of MMA | 2 (1.25) | 1 (1.33) | 1 (1.18) | 1.000 |
| Mean age at onset of first neurological symptoms (years) | 20.3 ± 17.04 | 5.1 ± 3.09 | 33.7 ± 12.40 | <0.001 |
| Mean age at diagnosis (years) | 22.8 ± 16.93 | 8.3 ± 6.52 | 33.5 ± 12.41 | <0.001 |
| Latency: first appearance of neurological symptoms to confirmed diagnosis (months) | 30.4 ± 58.14 | 39.3 ± 60.37 | 22.5 ± 55.26 | 0.001 |
| Presence of precipitating factor | 66 (41.3%) | 39 (52.0%) | 27 (31.8%) | 0.009 |
| MMS: MMD | 36: 124 | 12: 63 | 24: 61 | 0.087 |
Symptomatology of MMA patients at different instances of disease course.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
|
| |||
| First neurological symptom | Fixed motor weakness | 76 (47.5) | 33 (44.0) | 43 (50.6) | 0.431 |
| Transient ischemic attacks | 36 (22.5) | 20 (26.7) | 16 (18.8) | 0.184 | |
| Headache | 28 (17.5) | 7 (9.3) | 21 (24.7) | 0.012 | |
| Seizures | 15 (9.4) | 13 (17.3) | 2 (2.4) | <0.001 | |
| Cognitive and behavioral changes | 2 (1.3) | 1 (1.3) | 1 (1.2) | 1.000 | |
| Visual symptoms | 3 (1.9) | 1 (1.3) | 2 (2.4) | 1.000 | |
| Extra-pyramidal symptoms | — | — | — | ||
| Symptom at the time of presentation | Fixed motor weakness | 103 (64.4) | 42 (56.0) | 61 (71.8) | 0.047 |
| Transient ischemic attacks | 19 (11.9) | 14 (18.7) | 5 (5.9) | 0.015 | |
| Headache | 14 (8.8) | 5 (6.7) | 9 (10.6) | 0.416 | |
| Seizures | 11 (6.9) | 8 (10.7) | 4 (4.7) | 0.026 | |
| Cognitive and behavioral changes | 6 (3.6) | 1 (1.3) | 4 (4.7) | 0.623 | |
| Visual symptoms | 5 (3.1) | 3 (4.0) | 2 (2.4) | 0.666 | |
| Extra-pyramidal symptoms | 2 (1.3) | 2 (2.7) | — | 0.218 |
Frequency of transient and fixed neurological symptoms at different instances of disease course.
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
| ||
|
|
|
| ||
|
| ||||
| 1. Transient neurological symptoms | 79 (49.4) | 40 (53.3) | 39 (45.9) | 0.267 |
| (a) Perfusion dependent | 64 (40.0) | 27 (36.0) | 37 (43.5) | 0.423 |
| (b) Perfusion independent | 15 (9.4) | 13 (17.3) | 2 (2.4) | <0.001 |
| 2. Fixed neurological symptoms | 81 (50.6) | 35 (46.7) | 46 (54.1) | 0.428 |
|
| ||||
| 1. Transient neurological symptoms | 44 (27.5) | 27 (36.0) | 17 (20.0) | 0.018 |
| (a) Perfusion dependent | 33 (20.6) | 19 (25.3) | 14 (16.5) | 0.177 |
| (b) Perfusion independent | 11 (6.9) | 8 (10.7) | 3 (3.5) | 0.026 |
| 2. Fixed neurological symptoms | 116 (72.5) | 48 (64.0) | 68 (80.0) | 0.080 |
|
| ||||
| 1. Transient neurological symptoms | 140 (87.5) | 68 (90.7) | 72 (84.7) | 0.339 |
| (a) Perfusion dependent | 104 (65.0) | 40 (50.3) | 64 (75.3) | 0.005 |
| (b) Perfusion independent | 36 (22.5) | 28 (37.3) | 8 (9.4) | <0.001 |
| 2. Fixed neurological symptoms | 111 (69.4) | 50 (66.7) | 61 (71.8) | 0.497 |
Comparison between first neurological symptom and latency of diagnosis.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
|
| |||
| Transient neurological symptoms | All | 37.9 ± 67.87 | 43.6 ± 67.33 | 31.6 ± 68.79 | 0.045 |
| Perfusion dependent | 25.9 ± 42.02 | 29.4 ± 41.65 | 23.4 ± 42.71 | 0.125 | |
| Perfusion independent | 84.8 ± 117.10 | 71.1 ± 96.14 | 180.0 ± 254.56 | 0.937 | |
| Fixed neurological symptoms | 23.0 ± 46.00 | 33.9 ± 51.22 | 15.1 ± 40.56 | 0.133 | |
Frequency of type of MMA presentation.
|
|
|
|
|
|
|---|---|---|---|---|
|
|
|
|
| |
| TIA | 35 (21.9) | 20 (26.7) | 15 (17.7) | 0.184 |
| Infarction | 72 (45.0) | 34 (45.3) | 38 (44.7) | 1.000 |
| Hemorrhage | 15 (9.4) | — | 15 (17.7) | <0.001 |
| Headache | 21 (13.1) | 7 (9.3) | 14 (16.5) | 0.242 |
| Epilepsy | 15 (9.4) | 14 (18.7) | 1 (1.2) | <0.001 |
| Asymptomatic | ||||
| Others | 2 (1.3) | — | 2 (2.4) | 0.499 |
Radiological characteristics of MMA patients.
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
|
| |||
| Type of lesion | Infarct | 129 (80.6) | 66 (88.0) | 63 (74.1) | <0.001 |
| Hemorrhage | 18 (11.3) | 1 (1.3) | 17 (20.0) | ||
| No acute insult | 13 (8.1) | 8 (10.7) | 5 (5.9) | ||
| Pattern of infarct | (A) Cortical | 72 (45.0) | 43 (57.3) | 40 (47.1) | 0.004 |
| - Gyral pattern | 42 (26.3) | 28 (37.3) | 14 (16.5) | 0.004 | |
| (B) Subcortical | 17 (10.6) | 3 (4.0) | 14 (16.5) | 0.018 | |
| (C) Both cortical and subcortical | 33 (20.6) | 17 (22.7) | 16 (18.8) | 0.564 | |
| (D) Watershed | 64 (40.0) | 24 (32.0) | 40 (47.1) | 0.055 | |
| Posterior circulation stroke | 10 (6.3) | 7 (9.3) | 3 (3.5) | 0.191 | |
| Pattern of Hemorrhage | Intraparenchymal without IVH | 4 (2.5) | 1 (1.3) | 3 (3.5) | 0.002 |
| Primary IVH | 6 (3.8) | - | 6 (7.1) | ||
| Secondary IVH | 8 (5.0) | - | 8 (9.4) | ||
| Brain atrophy | 104 (65.0) | 54 (72.0) | 50 (58.8) | 0.098 | |
| “Ivy” sign | 115 (71.9) | 63 (84.0) | 52 (61.9) | 0.002 | |
| Posterior circulation involvement | 89 (55.6) | 44 (58.7) | 45 (52.9) | 0.525 | |
| Suzuki staging | Stage 1 | 1 (0.6) | 1 (1.3) | — | 0.018 |
| Stage 2 | 26 (16.3) | 6 (8.0) | 20 (23.5) | ||
| Stage 3 | 48 (30.0) | 25 (33.3) | 23 (27.1) | ||
| Stage 4 | 50 (31.3) | 30 (40.0) | 20 (23.5) | ||
| Stage 5 | 33 (20.6) | 12 (16.0) | 21 (24.7) | ||
| Stage 6 | 1 (0.6) | 1 (1.3) | — | ||
Comparison of diagnostic latency with radiological features.
|
|
|
|
|
|---|---|---|---|
|
|
|
| |
| Brain Atrophy | 37.8 ± 61.36 | 12.0 (0 – 36.0) | <0.001 |
| “Ivy” sign | 30.9 ± 55.44 | 12.0 (0 – 24.0) | 0.267 |
| Posterior circulation involvement | 34.3 ± 61.02 | 12.0 (0 – 36.0) | 0.106 |
Salient epidemiological features of MMA based on recent data from countries around the world.
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
|
| |||||||
| (i) Japan | 0.54–0.94 | 6.03–10.5 | 1.8–2.2:1 | Three peaks in male: 10–14, 35–39, 55–59, and two peaks in female: 20–24, 50–54. | 10–15 | 48.5–66 | 19–21 (Adult: 32.5–51) |
| (ii) Korea | 1.0–2.3 | 6.3–16.3 | 1.8–1.9 | Bimodal: 5–14 and 45–54 | 10–15 | 38.3–49.6 | 42.4 (Adult: 62.4–69) |
| (iii) Taiwan | 0.15–1.74 | 1.61 | 1.4:1 | Bimodal: 5–9 (males), 10–14 (female), and 40–44 | - | 46.7 | 26.5 |
| (iv) China | 0.42– 0.59 | 0.72– 1.01 | 1.1:1 | Bimodal: 5–9 and 35–45 | 5.2–7.5 | 40–70.8 | 14–55.9 |
|
| |||||||
| (i) Europe | 0.03–0.07 | 0.8 | 1.8–3.2 | Bimodal: 11–18 and 40–49 | 5.7 | 47–82 | 8.5–23 |
| (ii) USA | 0.086–0.57 | – | 1.4–4.3:1 | Bimodal: 1st and 4th decade | 2 | 21.4–79 | 6.4–29 |
Representative epidemiological data on Indian MMA from previous literature.
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
|
| |||||||||
| (i) Garg et al. ( | 44 (1:2.1) | 18 (41.9%) | 0 | N/A | 25.6 | 31.8 | 68.2 | N/A | N/A |
| (ii) Gupta et al. ( | 82 | 64 (78.1%) | 0 | N/A | 14 | 81.7 | 8.5 | N/A | Stage 5 (46.6%) |
|
| |||||||||
| (i) Tripathi et al. ( | 8 (1.8:1) | 8 (100%) | 0 | N/A | 7.6 | 100 | 0 | 12.5 | N/A |
| (ii) Patil et al. ( | 41 (1:1.2) | 41 (100%) | 8 (19.5%) | Nil | 6.3 | 92.7 | 0 | N/A | N/A |
|
| |||||||||
| (i) Sundaram et al. ( | 36 (1.3:1) | 15 (41.7%) | 10 (27.8%) | Nil | 17.5 | 63.9 | 27.8 | 0 | Stage 4 (47.2%) |
| (ii) Sadashiva et al. ( | 70 (1.1:1) | 54 (77.1%) | 0 | N/A | 13.8 (child- 8, adult- 33) | 90 | 10 | N/A | Stage 3 (76%) |
|
| |||||||||
| (i) Lahoti and Ray ( | 30 (1.2:1) | 30 (100%) | 0 | Nil | 6.7 | 96.7 | 3.3 | 13.3 | Stage 3 (44%) |
| (ii) Das et al. ( | 76 (1.5:1) | 36 (47.4%) | 14 (18.4%) | Nil | 18.1 (child-4.2, adult-31.5) | 81.6 | 13.2 | 56.6 | Stage 4 (41.7%) |